EP 862
Latest Information Update: 28 Mar 2008
Price :
$50 *
At a glance
- Originator EPIX Pharmaceuticals
- Class Gadolinium-containing contrast agents; Imaging agents; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 28 May 2003 No development reported - Preclinical for Magnetic resonance imaging in USA (unspecified route)
- 29 Mar 2000 Preclinical development for Magnetic resonance imaging in USA (Unknown route)